闅ㄨ憲鑵槫灏嶄汉椤炲仴搴风殑濞佽剠閫愭几鍔犲ぇ锛屼汉椤炲皪鐧岀櫏鐨勭窗(x矛)鑳炵敓鐗╁(xu茅)鍜岀敓鐗╅啱(y墨)瀛�(xu茅)鐮旂┒鏈変簡椋涢�熺殑鐧�(f膩)灞曪紝鐧屽熀鍥�銆佹姂鐧屽熀鍥犮�佺窗(x矛)鑳炲噵浜�銆佽叓鐦よ绠″舰鎴愮瓑浣胯叓鐦ょ爺绌剁敱绱�(x矛)鑳炵敓鐗╁(xu茅)姘村钩杞�(zhu菐n)璁婂埌鍒嗗瓙鐢熺墿瀛�(xu茅)姘村钩[1]銆備互鑶滀笂鎴栫窗(x矛)鑳炲収(n猫i)鐗圭暟鎬ц〃閬�(d谩)鎴栭珮琛ㄩ仈(d谩)鐨勫垎瀛愮偤浣滅敤闈堕粸锛屽寘鎷澏鍚戦叒姘ㄩ吀婵�閰�锛岃绠℃柊鐢燂紝鑵槫绱�(x矛)鑳炲懆鏈熺浉闂�(gu膩n)鍥犲瓙锛岀祫铔嬬櫧鍘讳箼閰伴叾鎶戝埗鍔戯紝寰挵(hu谩n)澧�锛岃叓鐦ゅ共绱�(x矛)鑳�锛岃叓鐦や唬璎濈暟甯哥瓑鍥犵礌鎴愮偤鐮旂┒闈堕粸鐗圭暟鎬ф姉鑵槫钘ョ墿鐨勯棞(gu膩n)閸�[2]銆傜櫨闈堝▉浣滅偤灏堟キ(y猫)瑭﹀姂渚涙噳(y墨ng)鍟�锛屽彲鎻愪緵120浣欑ó鑵槫鐮旂┒闈堕粸鎶戝埗鍔戝拰婵�娲诲姂鐢�(ch菐n)鍝�銆�
- 澶氱ó鐔遍杸闈堕粸鎶戝埗鍔�锛屾豢瓒冲墠娌跨鐮旈渶姹�
- 浣滅敤闈堕粸娓呮櫚锛屾槗浜庡鎴堕伕鎿�
- 鐢�(ch菐n)鍝佺磾搴﹂珮锛岃唱(zh矛)閲忕┅(w臎n)瀹�锛岀従(xi脿n)璨ㄤ緵鎳�(y墨ng)
.png)
鍦�1:Immunofluorescence and flow cytometric analyses of the translocation of ABCG2 in MCF-7 FLV1000 cells before and after treatment with the PI3K inhibitor LY294002[3].
References
[1] Mbengue A, Bhattacharjee S, Pandharkar T, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria[J]. Nature, 2015, 520(7549):683-7.
[2] Sapey E, Greenwood H, Walton G, Mann E, Love A, Aaronson N, Insall RH, Stockley RA, Lord JM: Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence[J]. Blood. 2014,123(2):239-248.
[3] To K K W, Tomlinson B. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists[J]. British Journal of Pharmacology, 2013, 170(5):1137–1151.
鈻� 鑵槫鐮旂┒鍖栧悎鐗�
|
鐢�(ch菐n)鍝佺法铏�
|
鑻辨枃鍚嶇ū
|
涓枃鍚嶇ū
|
CAS
|
浣滅敤闈堕粸
|
|
150037
|
5-Azacytidine, 99%
|
5-姘洔鑳炲槯鍟舵牳鑻�, 99%
|
320-67-2
|
DNA Methyltransferase鎶戝埗鍔�
|
|
268355
|
2-Amino-6-purinethiol, 98%
|
2-姘ㄥ熀-6-鍢屽懁纭唶, 98%
|
154-42-7
|
DNA Methyltransferase鎶戝埗鍔�
|
|
180939
|
5-Fluorouracil, 99%
|
5-姘熷翱鍢у暥, 99%
|
51-21-8
|
DNA/RNA Synthesis鎶戝埗鍔�
|
|
251696
|
Oxaliplatin, 95%
|
濂ф矙鍒╅墤, 95%
|
61825-94-3
|
DNA/RNA Synthesis鎶戝埗鍔�
|
|
258050
|
2-Chloro-2'-deoxyadenosine, 99%
|
2-姘�-2'-鑴哀鑵鸿嫹, 99%
|
4291-63-8
|
DNA/RNA Synthesis鎶戝埗鍔�
|
|
271269
|
Gemcitabine hydrochloride, 99%
|
楣介吀鍚夎タ浠栨勘, 99%
|
122111-03-9
|
DNA/RNA Synthesis鎶戝埗鍔�
|
|
274584
|
Carboplatin, 98%
|
纰抽墤, 98%
|
41575-94-4
|
DNA/RNA Synthesis鎶戝埗鍔�
|
|
275688
|
cis-Diamineplatinum(II) dichloride, 99%
|
闋嗗紡-浜屾皑浜屾隘鍖栭墤, 99%
|
15663-27-1
|
DNA/RNA Synthesis鎶戝埗鍔�
|
|
381488
|
Ara-G hydrate, 98%
|
闃跨硸槌ヨ嫹, 98%
|
38819-10-2
|
DNA/RNA synthesis鎶戝埗鍔�
|
|
341249
|
Erlotinib, 98%
|
鍩冪緟鏇垮凹, 98%
|
183321-74-6
|
EGFR鎶戝埗鍔�
|
|
795123
|
Lapatinib ditosylate, 98%
|
浜岀敳鑻：閰告媺甯曟浛灏�, 98%
|
388082-77-7
|
EGFR鎶戝埗鍔�
|
|
831262
|
Lapatinib, 98%
|
鎷夊笗鏇垮凹, 98%
|
231277-92-2
|
EGFR鎶戝埗鍔�
|
|
996037
|
Afatinib, 98%
|
闃挎硶鏇垮凹, 98%
|
850140-72-6
|
EGFR鎶戝埗鍔�
|
|
303595
|
Trichostatin A, 98%
|
鏇插彜鏌宠弻绱�A, 98%
|
58880-19-6
|
HDAC鎶戝埗鍔�
|
|
628151
|
Vorinostat, 99%
|
浼忕珛璜句粬, 99%
|
149647-78-9
|
HDAC鎶戝埗鍔�
|
|
625238
|
Entinostat, 99%
|
鎭╂浛璜剧壒, 99%
|
209783-80-2
|
HDAC鎶戝埗鍔�
|
|
837002
|
Panobinostat, 98%
|
甯曟瘮鍙镐粬, 98%
|
404950-80-7
|
HDAC鎶戝埗鍔�
|
|
1349106
|
Ruxolitinib phosphate salt, 99%
|
榄储鍒╂浛灏肩７閰搁菇, 99%
|
1092939-17-7
|
JAK鎶戝埗鍔�
|
|
1430418
|
Tofacitinib citrate, 99%
|
妾告閰告墭娉曟浛灏�, 99%
|
540737-29-9
|
JAK鎶戝埗鍔�
|
|
912849
|
Tofacitinib, 99%
|
鎵樻硶鏇垮凹, 99%
|
477600-75-2
|
JAK鎶戝埗鍔�
|
|
951485
|
Ruxolitinib, 99%
|
榄储鏇垮凹, 99%
|
941678-49-5
|
JAK鎶戝埗鍔�
|
|
1272662
|
Cabazitaxel, 99%
|
鍗″反浠栬辰, 99%
|
183133-96-2
|
Microtubule Associated鎶戝埗鍔�
|
|
181603
|
Docetaxel, 98%
|
澶氳タ浠栬辰, 98%
|
114977-28-5
|
Microtubule Associated鎶戝埗鍔�
|
|
266725
|
Combretastatin A-4, 98%
|
搴锋櫘鐟炴眬, 98%
|
117048-59-6
|
Microtubule Associated鎶戝埗鍔�
|
|
369172
|
6-Amino-3-methylpurine, 90%
|
6-姘ㄥ熀-3-鐢插熀鍢屽懁, 90%
|
5142-23-4
|
PI3K鎶戝埗鍔�
|
|
268623
|
Quercetin, 98%
|
妲茬毊绱�, 98%
|
117-39-5
|
PI3K鎶戝埗鍔�
|
|
114089
|
7-Ethyl-10-hydroxycamptothecin, 99%
|
7-涔欏熀-10-缇ュ熀鍠滄ü鍫�, 99%
|
86639-52-3
|
Topoisomerase鎶戝埗鍔�
|
|
116557
|
Daunorubicin hydrochloride, 97%
|
閬撹闇夌礌楣介吀楣�, 97%
|
23541-50-6
|
Topoisomerase鎶戝埗鍔�
|
|
194237
|
Epirubicin hydrochloride, 98%
|
琛ㄦ煍姣旀槦楣介吀楣�, 98%
|
56390-09-1
|
Topoisomerase鎶戝埗鍔�
|
|
814262
|
Vandetanib, 99%
|
鍑″痉浠栧凹, 99%
|
443913-73-3
|
VEGFR2鎶戝埗鍔�
|
|
1109982
|
Vatalanib dihydrochloride, 99%
|
鐡︿粬鎷夊凹鍫夸簩楣介吀楣�, 99%
|
212141-51-0
|
VEGFR2鎶戝埗鍔�
|
|
1239124
|
Ponatinib, 99%
|
甯曠磵鏇垮凹, 99%
|
943319-70-8
|
VEGFR2鎶戝埗鍔�
|
|
812864
|
Axitinib, 98%
|
闃胯タ鏇垮凹, 98%
|
319460-85-0
|
VEGFR2鎶戝埗鍔�
|
|
1386067
|
A 769662, 98%
|
A 769662, 98%
|
844499-71-4
|
AMPK婵�娲诲姂
|
鈻� 鐩搁棞(gu膩n)鐢�(ch菐n)鍝侊細